scispace - formally typeset
R

Ronald Klein

Researcher at University of Wisconsin-Madison

Publications -  1306
Citations -  163459

Ronald Klein is an academic researcher from University of Wisconsin-Madison. The author has contributed to research in topics: Population & Diabetes mellitus. The author has an hindex of 194, co-authored 1305 publications receiving 149140 citations. Previous affiliations of Ronald Klein include Los Angeles Biomedical Research Institute & Wake Forest University.

Papers
More filters
Journal ArticleDOI

Expansive gene transfer in the rat CNS rapidly produces amyotrophic lateral sclerosis relevant sequelae when TDP-43 is overexpressed.

TL;DR: The expression pattern encompassed the distribution of neuropathology of ALS, and could provide a rapid, relevant screening assay for TDP-43 variants and other disease-related proteins, as well as aiding studying diseases that affect both the spinal cord and brain.
Journal ArticleDOI

Retinal Microvascular Abnormalities Predict Progression of Brain Microvascular Disease An Atherosclerosis Risk in Communities Magnetic Resonance Imaging Study

TL;DR: In this paper, the authors investigated if either leukoaraiosis volume progression measured continuously or combined with incident lacunar infarcts would better demonstrate expected associations with retinal disease than has previously been shown.
Journal ArticleDOI

Weight Gain Associated With Improved Glycemic Control in Population-Based Sample of Subjects With Type I Diabetes

TL;DR: Weight gain was significantly associated with improvements in glycosylated hemoglobin levels and change in the treatment regimen from one type of insulin to a combination of short- and long-acting insulins and was correlated with increases in the number of shots of insulin per day.
Journal ArticleDOI

Development and Application of a Model to Estimate the Impact of Type 1 Diabetes on Health-Related Quality of Life

TL;DR: The augmented model can estimate quality-adjusted life years (QALYs) as well as costs associated with type 1 diabetes on any population of interest over any period of time and enables health planners to perform cost-effectiveness analyses to compare alternative treatment strategies and support subsequent decision making.